Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)

Hala M. Alshayeb, Leigh Quarles

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Loss of glomerular filtration and other renal functions in chronic kidney disease leads to complex abnormalities of mineral homeostasis, referred to as mineral and bone disorder, all causing mortality. This chapter discusses the pathophysiology, pathogenesis, diagnosis, and treatment of chronic kidney disease mineral bone disorder (CKD-MBD). Three hormones [PTH, fibroblast growth factor 23 (FGF23), and 1,25(OH)2D] and four organ systems [parathyroid gland (PTG), bone, small intestines, and kidney] are involved in regulation mineral homeostasis. Initial secretion of FGF23 by the bone triggered by unknown stimuli is the inciting event leading to secondary hyperparathyroidism in CKD. Currently, other than bone biopsies, there is no diagnostic test that identifies the different subtypes of bone diseases in CKD. Treatment considerations depend on the stage of CKD, the mechanism of action of the various therapeutic agents, potential toxicities associated with various treatments, and cost/reimbursement of the various therapies.

Original languageEnglish (US)
Title of host publicationPrimer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
Subtitle of host publicationEighth Edition
PublisherWiley-Blackwell
Pages640-650
Number of pages11
ISBN (Electronic)9781118453926
ISBN (Print)9781118453889
DOIs
StatePublished - Jul 19 2013

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Minerals
Bone
Bone and Bones
Homeostasis
Kidney
Fibroblast Growth Factor 1
Secondary Hyperparathyroidism
Parathyroid Glands
Bone Diseases
Chronic Renal Insufficiency
Routine Diagnostic Tests
Health Care Costs
Small Intestine
Biopsy
Hormones
Toxicity
Mortality
Therapeutics
fibroblast growth factor 23

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Alshayeb, H. M., & Quarles, L. (2013). Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition (pp. 640-650). Wiley-Blackwell. https://doi.org/10.1002/9781118453926.ch78

Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). / Alshayeb, Hala M.; Quarles, Leigh.

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell, 2013. p. 640-650.

Research output: Chapter in Book/Report/Conference proceedingChapter

Alshayeb, HM & Quarles, L 2013, Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell, pp. 640-650. https://doi.org/10.1002/9781118453926.ch78
Alshayeb HM, Quarles L. Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell. 2013. p. 640-650 https://doi.org/10.1002/9781118453926.ch78
Alshayeb, Hala M. ; Quarles, Leigh. / Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Eighth Edition. Wiley-Blackwell, 2013. pp. 640-650
@inbook{8aa33afacf104183aae886771a9e6a5b,
title = "Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)",
abstract = "Loss of glomerular filtration and other renal functions in chronic kidney disease leads to complex abnormalities of mineral homeostasis, referred to as mineral and bone disorder, all causing mortality. This chapter discusses the pathophysiology, pathogenesis, diagnosis, and treatment of chronic kidney disease mineral bone disorder (CKD-MBD). Three hormones [PTH, fibroblast growth factor 23 (FGF23), and 1,25(OH)2D] and four organ systems [parathyroid gland (PTG), bone, small intestines, and kidney] are involved in regulation mineral homeostasis. Initial secretion of FGF23 by the bone triggered by unknown stimuli is the inciting event leading to secondary hyperparathyroidism in CKD. Currently, other than bone biopsies, there is no diagnostic test that identifies the different subtypes of bone diseases in CKD. Treatment considerations depend on the stage of CKD, the mechanism of action of the various therapeutic agents, potential toxicities associated with various treatments, and cost/reimbursement of the various therapies.",
author = "Alshayeb, {Hala M.} and Leigh Quarles",
year = "2013",
month = "7",
day = "19",
doi = "10.1002/9781118453926.ch78",
language = "English (US)",
isbn = "9781118453889",
pages = "640--650",
booktitle = "Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism",
publisher = "Wiley-Blackwell",
address = "United Kingdom",

}

TY - CHAP

T1 - Treatment of Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)

AU - Alshayeb, Hala M.

AU - Quarles, Leigh

PY - 2013/7/19

Y1 - 2013/7/19

N2 - Loss of glomerular filtration and other renal functions in chronic kidney disease leads to complex abnormalities of mineral homeostasis, referred to as mineral and bone disorder, all causing mortality. This chapter discusses the pathophysiology, pathogenesis, diagnosis, and treatment of chronic kidney disease mineral bone disorder (CKD-MBD). Three hormones [PTH, fibroblast growth factor 23 (FGF23), and 1,25(OH)2D] and four organ systems [parathyroid gland (PTG), bone, small intestines, and kidney] are involved in regulation mineral homeostasis. Initial secretion of FGF23 by the bone triggered by unknown stimuli is the inciting event leading to secondary hyperparathyroidism in CKD. Currently, other than bone biopsies, there is no diagnostic test that identifies the different subtypes of bone diseases in CKD. Treatment considerations depend on the stage of CKD, the mechanism of action of the various therapeutic agents, potential toxicities associated with various treatments, and cost/reimbursement of the various therapies.

AB - Loss of glomerular filtration and other renal functions in chronic kidney disease leads to complex abnormalities of mineral homeostasis, referred to as mineral and bone disorder, all causing mortality. This chapter discusses the pathophysiology, pathogenesis, diagnosis, and treatment of chronic kidney disease mineral bone disorder (CKD-MBD). Three hormones [PTH, fibroblast growth factor 23 (FGF23), and 1,25(OH)2D] and four organ systems [parathyroid gland (PTG), bone, small intestines, and kidney] are involved in regulation mineral homeostasis. Initial secretion of FGF23 by the bone triggered by unknown stimuli is the inciting event leading to secondary hyperparathyroidism in CKD. Currently, other than bone biopsies, there is no diagnostic test that identifies the different subtypes of bone diseases in CKD. Treatment considerations depend on the stage of CKD, the mechanism of action of the various therapeutic agents, potential toxicities associated with various treatments, and cost/reimbursement of the various therapies.

UR - http://www.scopus.com/inward/record.url?scp=85018588053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018588053&partnerID=8YFLogxK

U2 - 10.1002/9781118453926.ch78

DO - 10.1002/9781118453926.ch78

M3 - Chapter

SN - 9781118453889

SP - 640

EP - 650

BT - Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism

PB - Wiley-Blackwell

ER -